Akèy › Limfòm Non-Hodgkin › Texas › Houston
Etid klinik pou Limfòm Non-Hodgkin nan Houston, TX
31 etid pou Limfòm Non-Hodgkin ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
- Md Anderson Cancer Center, Houston
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Ap rekriteFaz 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Ap rekriteFaz 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Ap rekriteFaz 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Ap rekriteEtid obsèvasyon
- Texas Children's Hospital, Houston
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Ap rekriteFaz 1
- Baylor College of Medicine, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Ap rekriteFaz 1
- Md Anderson Cancer Center, Houston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Ap rekriteFaz 1/2
- Research Site, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Ap rekriteFaz 2
- Research Site, Houston
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Ap rekriteFaz 1
- Clinical Trial Site, Houston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Ap rekriteFaz 3
- MD Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center, Houston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- M.D. Anderson Cancer Center, Houston
- Texas Children's Hospital - Baylor Medical Center, Houston
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
Ap rekriteFaz 1
- Harris Health System - Ben Taub General Hospital/Smith Clinic, Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
- ak 1 plis
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Ap rekriteFaz 1
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Ap rekriteFaz 4
- University of Texas MD Anderson Cancer Center, Houston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Ap rekriteFaz 4
- University of Texas MD Anderson Cancer Center, Houston
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Ap rekriteFaz 2
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Ap rekriteFaz 1/2
- University of Texas MD Anderson Cancer Center, Houston
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Etid Limfòm Non-Hodgkin nan lòt vil
- New York City, NY31 etid
- Boston, MA26 etid
- Nashville, TN21 etid
- Philadelphia, PA20 etid
- Baldwin Park, CA19 etid
- Washington, DC18 etid
- Chicago, IL18 etid
- Milwaukee, WI18 etid
- Atlanta, GA18 etid
- Columbus, OH18 etid
- Dallas, TX17 etid
- Seattle, WA16 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.